ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCUs immunotherapies product pipeline comprises ICT-107, ICT-140 and ICT-121. ICT-107, the lead product candidate of the company is being developed for the treatment of glioblastoma multiforme (GBM); ICT-140, a DC vaccine designed to treat recurrent ovarian cancer; and ICT-121 for the treatment of recurrent GBM and other solid tumors. The company also develops stem cell therapies for treating cancer. As of March 2015, the development of ICT-140 has been put on hold. IMCU is headquartered in Calabasas, California, the US.

ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
Licensing Agreements 19
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
Equity Offering 23
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd - Key Competitors 34
ImmunoCellular Therapeutics Ltd - Key Employees 35
ImmunoCellular Therapeutics Ltd - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Financial Announcements 37
May 14, 2018: ImmunoCellular Therapeutics Reports First Quarter 2018 Financial Results 37
Mar 13, 2018: ImmunoCellular Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 38
Nov 21, 2017: ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results 39
Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 40
May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 41
Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 42
Product News 44
12/13/2017: ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 44
Apr 12, 2018: ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program 45
Other Significant Developments 46
Feb 13, 2018: ImmunoCellular Therapeutics Announces Update on Financial Condition 46
Aug 23, 2017: ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List Of Tables

List of Tables
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoCellular Therapeutics to Enter into Agreement with Memgen 13
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University 14
ImmunoCellular Therapeutics Enters into Research Agreement with University of Maryland, Baltimore 15
ImmunoCellular Therapeutics Enters into Agreement with Canadian Brain Tumour Consortium 16
ImmunoCellular Therapeutics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 17
ImmunoCellular Therapeutics Enters into Agreement with Pure MHC 18
ImmunoCellular Therapeutics Enters into Licensing Agreement with California Institute of Technology 19
ImmunoCellular Enters Into Licensing Agreement With University of Pittsburgh 20
ImmunoCellular Amends Licensing Agreement With Johns Hopkins University 21
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 22
ImmunoCellular Therapeutics Raises USD5 Million in Public Offering of Units 23
ImmunoCellular Therapeutics Files for Rights Offering 25
ImmunoCellular Therapeutics Prices Public Offering of Shares and Warrants for USD7.5 Million 26
ImmunoCellular Plans to Raise Funds through Public Offering of Shares 28
ImmunoCellular Therapeutics Raises USD16 Million in Public Offering of Shares and Warrants 29
ImmunoCellular Therapeutics Decreases Size Of Public Offering Of Shares For US$17 Million 30
ImmunoCellular Therapeutics Completes Public Offering Of Shares For US$21 Million 31
ImmunoCellular Therapeutics Completes Public Offering Of Units For US$10.4 Million 33
ImmunoCellular Therapeutics Ltd, Key Competitors 34
ImmunoCellular Therapeutics Ltd, Key Employees 35
ImmunoCellular Therapeutics Ltd, Subsidiaries 36
ImmunoCellular Therapeutics Ltd, Joint Venture 36

List Of Figures

List of Figures
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoCellular Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoCellular Therapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 10

ImmunoCellular Therapeutics Ltd (IMUC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented

USD 250 View Report

ImmunoCellular Therapeutics, Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

ImmunoCellular Therapeutics, Ltd Company Profile is a detailed strategic and analytical report on ImmunoCellular Therapeutics, Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available